score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.M918T	0.2871	209.0	0.0	0.0		Putatively Actionable	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.M918T (Missense)		PCPG_CONSENSUS2	TCGA-QT-A5XK-01A-11D-A35D-08	TCGA-QT-A5XK-10A-01D-A35B-08
Putatively Actionable	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.M918T	0.2575	167.0	0.0	0.0		Putatively Actionable	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.M918T (Missense)		PCPG_CONSENSUS2	TCGA-QT-A5XM-01A-11D-A35D-08	TCGA-QT-A5XM-10A-01D-A35B-08
Putatively Actionable	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.M918T	0.3971	136.0	0.0	0.0		Putatively Actionable	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.M918T (Missense)		PCPG_CONSENSUS2	TCGA-WB-A80V-01A-12D-A35I-08	TCGA-WB-A80V-10A-01D-A35G-08
Putatively Actionable	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.M918T	0.2985	134.0	0.0	0.0		Putatively Actionable	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.M918T (Missense)		PCPG_CONSENSUS2	TCGA-WB-A819-01A-11D-A35I-08	TCGA-WB-A819-10A-01D-A35G-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.G469A	0.6031	131.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.G469A (Missense)	1	PCPG_CONSENSUS2	TCGA-RX-A8JQ-01A-11D-A35D-08	TCGA-RX-A8JQ-10A-01D-A35B-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.C515S	0.3333	18.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.C515S (Missense)		PCPG_CONSENSUS2	TCGA-SP-A6QK-01A-11D-A35I-08	TCGA-SP-A6QK-10A-01D-A35G-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.D631Y	0.4	50.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.D631Y (Missense)		PCPG_CONSENSUS2	TCGA-W2-A7HA-01B-11D-A35I-08	TCGA-W2-A7HA-10C-01D-A35G-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.C634R	0.2955	44.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.C634R (Missense)		PCPG_CONSENSUS2	TCGA-SP-A6QK-01A-11D-A35I-08	TCGA-SP-A6QK-10A-01D-A35G-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.G1378D	0.2	100.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.G1378D (Missense)		PCPG_CONSENSUS2	TCGA-QR-A700-01A-11D-A35D-08	TCGA-QR-A700-10A-01D-A35B-08
Investigate Actionability	Inferential			Mutational Signature	COSMIC Signature 3	version 2	0.281						Investigate Actionability	Platinum	Platinum-based chemotherapy	Chemotherapy	Responders to platinum based chemotherapy exhibit COSMIC signature 3 (HR signature) mutations in pancreatic cancer.	Alexandrov LB, Nik-zainal S, Siu HC, Leung SY, Stratton MR. A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun. 2015;6:8683.	https://doi.org/10.1038/ncomms9683																	COSMIC Signature (version 2) 3 (28%)		PCPG_CONSENSUS2		
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.M1128V	0.1685	89.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.M1128V (Missense)		PCPG_CONSENSUS2	TCGA-QR-A700-01A-11D-A35D-08	TCGA-QR-A700-10A-01D-A35B-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.M329L	0.2535	71.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.M329L (Missense)		PCPG_CONSENSUS2	TCGA-WB-A80Q-01A-11D-A35I-08	TCGA-WB-A80Q-10A-01D-A35G-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.H108Afs*2	0.4255	94.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.H108Afs*2 (Frameshift)		PCPG_CONSENSUS2	TCGA-RT-A6Y9-01A-12D-A35D-08	TCGA-RT-A6Y9-10B-01D-A35B-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.Y462S	0.3571	56.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.Y462S (Missense)		PCPG_CONSENSUS2	TCGA-QR-A70I-01A-11D-A35D-08	TCGA-QR-A70I-10A-01D-A35B-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.N16H	0.7167	60.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.N16H (Missense)		PCPG_CONSENSUS2	TCGA-QR-A6GO-01A-11D-A35D-08	TCGA-QR-A6GO-10A-01D-A35B-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.C3097R	0.3361	122.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.C3097R (Missense)	0	PCPG_CONSENSUS2	TCGA-QR-A70H-01A-12D-A35D-08	TCGA-QR-A70H-10A-01D-A35B-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.2963	81.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		PCPG_CONSENSUS2	TCGA-W2-A7HH-01A-11D-A35I-08	TCGA-W2-A7HH-10C-01D-A35G-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.A724V	0.4219	64.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.A724V (Missense)	0	PCPG_CONSENSUS2	TCGA-W2-A7HC-01A-11D-A35I-08	TCGA-W2-A7HC-10C-01D-A35G-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Deletion	p.F53_Q58delinsL	0.1803	122.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.F53_Q58delinsL (Deletion)	0	PCPG_CONSENSUS2	TCGA-SQ-A6I4-01A-11D-A35I-08	TCGA-SQ-A6I4-10A-01D-A35G-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.L562F	0.1833	120.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.L562F (Missense)		PCPG_CONSENSUS2	TCGA-WB-A81G-01A-11D-A35I-08	TCGA-WB-A81G-10A-01D-A35G-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.E1060G	0.072	125.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.E1060G (Missense)		PCPG_CONSENSUS2	TCGA-WB-A819-01A-11D-A35I-08	TCGA-WB-A819-10A-01D-A35G-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.D939N	0.3647	85.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.D939N (Missense)		PCPG_CONSENSUS2	TCGA-P7-A5NX-01A-11D-A35D-08	TCGA-P7-A5NX-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.I2500F	0.24	75.0	0.0	0.0																									MTOR p.I2500F (Missense)		PCPG_CONSENSUS2	TCGA-QR-A6GX-01A-11D-A35D-08	TCGA-QR-A6GX-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	CDKN2C	Missense	p.G137R	0.48	25.0	0.0	0.0																									CDKN2C p.G137R (Missense)		PCPG_CONSENSUS2	TCGA-PR-A5PH-01A-11D-A35D-08	TCGA-PR-A5PH-10B-01D-A35B-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.G690R	0.1212	66.0	0.0	0.0																									FGFR2 p.G690R (Missense)		PCPG_CONSENSUS2	TCGA-QR-A70A-01A-11D-A35D-08	TCGA-QR-A70A-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	POLE2	Missense	p.S65C	0.3158	38.0	0.0	0.0																									POLE2 p.S65C (Missense)		PCPG_CONSENSUS2	TCGA-QR-A70G-01B-11D-A35D-08	TCGA-QR-A70G-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.K189Nfs*2	0.6	15.0	0.0	0.0																									NF1 p.K189Nfs*2 (Frameshift)		PCPG_CONSENSUS2	TCGA-RW-A688-01A-11D-A35D-08	TCGA-RW-A688-10B-01D-A35B-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q400*	0.7692	52.0	0.0	0.0																									NF1 p.Q400* (Nonsense)		PCPG_CONSENSUS2	TCGA-RW-A67Y-01A-11D-A35D-08	TCGA-RW-A67Y-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.S413*	0.4505	111.0	0.0	0.0																									NF1 p.S413* (Nonsense)		PCPG_CONSENSUS2	TCGA-RW-A7D0-01A-11D-A35D-08	TCGA-RW-A7D0-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.K428Nfs*41	0.6471	34.0	0.0	0.0																									NF1 p.K428Nfs*41 (Frameshift)		PCPG_CONSENSUS2	TCGA-S7-A7WL-01A-11D-A35I-08	TCGA-S7-A7WL-10A-01D-A35G-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.L492Ffs*7	0.6129	31.0	0.0	0.0																									NF1 p.L492Ffs*7 (Frameshift)		PCPG_CONSENSUS2	TCGA-S7-A7WM-01A-12D-A35I-08	TCGA-S7-A7WM-10A-01D-A35G-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X509_splice	0.6923	13.0	0.0	0.0																									NF1 p.X509_splice (Splice Site)		PCPG_CONSENSUS2	TCGA-QR-A6GS-01A-11D-A35D-08	TCGA-QR-A6GS-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.W784R	0.4348	46.0	0.0	0.0																									NF1 p.W784R (Missense)		PCPG_CONSENSUS2	TCGA-RW-A685-01A-11D-A35D-08	TCGA-RW-A685-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.K874*	0.701	97.0	0.0	0.0																									NF1 p.K874* (Frameshift)		PCPG_CONSENSUS2	TCGA-SQ-A6I6-01A-11D-A35I-08	TCGA-SQ-A6I6-10A-01D-A35G-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.R997T	0.7636	55.0	0.0	0.0																									NF1 p.R997T (Missense)		PCPG_CONSENSUS2	TCGA-RT-A6YA-01A-12D-A35D-08	TCGA-RT-A6YA-10B-01D-A35B-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.F1346Sfs*27	0.2381	126.0	0.0	0.0																									NF1 p.F1346Sfs*27 (Frameshift)		PCPG_CONSENSUS2	TCGA-WB-A81V-01A-11D-A35I-08	TCGA-WB-A81V-10A-01D-A35G-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.G1532Efs*42	0.6949	59.0	0.0	0.0																									NF1 p.G1532Efs*42 (Frameshift)		PCPG_CONSENSUS2	TCGA-RW-A689-01A-11D-A35D-08	TCGA-RW-A689-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.C1878*	0.3509	57.0	0.0	0.0																									NF1 p.C1878* (Nonsense)		PCPG_CONSENSUS2	TCGA-WB-A81V-01A-11D-A35I-08	TCGA-WB-A81V-10A-01D-A35G-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.P2310Sfs*16	0.44	25.0	0.0	0.0																									NF1 p.P2310Sfs*16 (Frameshift)		PCPG_CONSENSUS2	TCGA-WB-A818-01A-11D-A35I-08	TCGA-WB-A818-10A-01D-A35G-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.R345S	0.1507	73.0	0.0	0.0																									TPX2 p.R345S (Missense)		PCPG_CONSENSUS2	TCGA-P8-A6RX-01A-11D-A35D-08	TCGA-P8-A6RX-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.N546K	0.4265	136.0	0.0	0.0																									FGFR1 p.N546K (Missense)		PCPG_CONSENSUS2	TCGA-QR-A70U-01A-11D-A35D-08	TCGA-QR-A70U-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.N546K	0.4459	74.0	0.0	0.0																									FGFR1 p.N546K (Missense)		PCPG_CONSENSUS2	TCGA-RW-A684-01A-12D-A35D-08	TCGA-RW-A684-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.P318L	0.2841	176.0	0.0	0.0																									RUNX1T1 p.P318L (Missense)		PCPG_CONSENSUS2	TCGA-QT-A5XL-01A-11D-A35D-08	TCGA-QT-A5XL-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.R124C	0.4783	46.0	0.0	0.0																									CDKN2A p.R124C (Missense)		PCPG_CONSENSUS2	TCGA-QR-A6H6-01A-11D-A35D-08	TCGA-QR-A6H6-10A-01D-A35B-08
Biologically Relevant				Mutational Signature	COSMIC Signature 12	version 2	0.472																													COSMIC Signature (version 2) 12 (47%)		PCPG_CONSENSUS2		
